PolyPeptide Group AG (PPGN) AI Stock Analysis

• Market Cap: CHF729.99M
• Dividend Yield: N/A
• Average Volume (3M): 35.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 3.15%
• EPS Growth: 62.88%
• Country: CH
• Employees: 1,362
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.56
• Shares Outstanding: 33,125,000
• 10 Day Avg. Volume: 33,284
• 30 Day Avg. Volume: 35,418
• PEG Ratio: 0.82
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 260.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF31.00
• Price Target Upside: 44.86% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 61 Neutral
• Price Target: CHF21.50 ▲(0.47%Upside)

PolyPeptide Group AG's overall score is driven by strong cash flow management and positive short-term technical indicators, offset by profitability issues and unappealing valuation metrics. Addressing profitability would significantly enhance the company's financial standing.

PolyPeptide Group AG Business Overview & Revenue Model

Company Description

PolyPeptide Group AG (PPGN) is a leading contract development and manufacturing organization (CDMO) specializing in the production of peptide-based active pharmaceutical ingredients (APIs). Operating within the pharmaceutical and biotechnology sectors, the company leverages its extensive expertise and advanced technologies to provide high-quality peptide synthesis and manufacturing services. PolyPeptide Group serves a global clientele, including pharmaceutical companies, research institutions, and biotech firms, helping them bring innovative peptide therapies to market.

How the Company Makes Money

PolyPeptide Group AG generates revenue primarily through its contract manufacturing services for peptide-based APIs. The company operates a business-to-business model, offering custom synthesis, development, and large-scale manufacturing solutions to pharmaceutical and biotech companies. Revenue streams are largely driven by long-term partnerships and contracts with these clients, who rely on PolyPeptide for its specialized capabilities in peptide production. In addition to manufacturing contracts, the company benefits from its established reputation and expertise, which contribute to a steady flow of orders and collaborations. The company's earnings are further supported by its focus on innovation and quality, ensuring compliance with regulatory standards and meeting the evolving needs of the pharmaceutical industry.

PolyPeptide Group AG Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
320.37M	338.69M	320.37M	280.98M	282.13M	224.30M
	Gross Profit
4.77M	39.27M	4.64M	51.99M	99.70M	73.19M
	EBIT
-33.83M	-7.36M	-36.47M	12.53M	67.40M	44.31M
	EBITDA
-12.31M	28.42M	-22.15M	35.72M	83.35M	58.55M
	Net Income Common Stockholders
-51.44M	-19.56M	-51.44M	7.77M	47.26M	31.34M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.38M	68.28M	95.71M	37.53M	136.30M	17.21M
	Total Assets
76.29M	756.58M	689.09M	575.78M	595.04M	375.98M
	Total Debt
8.84M	94.12M	113.66M	21.22M	18.00M	37.43M
	Net Debt
4.46M	25.84M	17.96M	-16.31M	-118.30M	20.23M
	Total Liabilities
38.93M	399.33M	307.86M	154.10M	173.87M	198.31M
	Stockholders Equity
37.35M	357.24M	381.23M	421.68M	421.17M	177.66M
Cash Flow		Free Cash Flow
-16.41M	2.43M	-20.25M	-69.64M	-16.61M	8.86M
	Operating Cash Flow
36.48M	89.40M	36.48M	5.46M	57.35M	49.48M
	Investing Cash Flow
-59.51M	-91.02M	-59.51M	-78.44M	-80.84M	-42.56M
	Financing Cash Flow
84.55M	-25.32M	84.55M	-26.87M	130.93M	-6.73M

PolyPeptide Group AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:PPGN, the sentiment is Positive. The current price of 21.4 is above the 20-day moving average (MA) of 20.04, above the 50-day MA of 18.21, and below the 200-day MA of 24.92, indicating a neutral trend. The MACD of 0.75 indicates Negative momentum. The RSI at 68.83 is Neutral, neither overbought nor oversold. The STOCH value of 88.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:PPGN.

PolyPeptide Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BANB	76 Outperform	CHF4.05B	33.64	8.87%	1.57%	4.84%	7.45%
SFZN	74 Outperform	$4.38B	26.14	18.36%	0.40%	1.82%	39.11%
COPN	73 Outperform	CHF1.01B	7.73	29.55%	3.26%	182.25%	―
PPGN	61 Neutral	CHF729.99M	―		―	3.15%	62.88%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%

PolyPeptide Group AG Corporate Events

PolyPeptide Expands Credit Facility to Fuel Growth

PolyPeptide Group AG has expanded its revolving credit facility by EUR 40 million to EUR 151 million, with an extension until March 2028, supported by UBS, Danske Bank, and Zürcher Kantonalbank. This financial boost, alongside increased support from main shareholder Draupnir Holding B.V., enhances PolyPeptide’s financial flexibility to pursue growth, aiming to double its 2023 revenues by 2028, particularly in the metabolic diseases and GLP-1 sectors.

The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF33.50 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.

PolyPeptide Group AG’s Shareholders Approve Key Proposals at 2025 General Meeting

At the fourth ordinary General Meeting, PolyPeptide Group AG’s shareholders approved all Board of Directors’ proposals, including re-elections and the introduction of new authorized and conditional share capital. These decisions are expected to strengthen the company’s financial structure and governance, potentially enhancing its market position and stakeholder confidence.

PolyPeptide Group AG Announces Agenda for 2025 General Meeting

PolyPeptide Group AG has announced the agenda for its fourth ordinary General Meeting in April 2025, where key board members will stand for re-election, and a new independent member, Jo LeCouilliard, is proposed for election. The meeting will also address the introduction of authorized and conditional share capital to enhance financial and strategic flexibility, alongside other standard agenda items such as re-election of auditors and approval of financial statements.

PolyPeptide Group AG Reports Strong 2024 Results and Growth Outlook for 2025

PolyPeptide Group AG reported significant improvements in profitability and cash flow for 2024, with a revenue increase of 5.1% compared to 2023. The company is poised for strong growth, driven by operational performance and capacity expansion projects in Belgium, France, and Sweden. For 2025, PolyPeptide forecasts accelerated revenue growth of 10% to 20%, supported by new commercial production in Belgium, and plans to continue increasing its EBITDA margin. The nomination of Joanna LeCouilliard to the Board of Directors is expected to bring valuable expertise in finance and healthcare management.